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Communicating the Risk of MRSA: The Role of Clinical Practice, Regulation and Other 
Policies in Five European Countries 
 
Introduction  
Healthcare associated infections (HCAIs) place a significant burden on health systems in 
terms of both morbidity and mortality, and their effects are felt far beyond just those utilising 
healthcare services  [1]. An already serious situation is now being exacerbated by the growth 
of antibiotic-resistant bacteria, such as meticillin-resistant Staphylococcus aureus (MRSA). 
MRSA is a bacterium which is resistant to ß-lactam antibiotics, a group of antibiotic 
treatments which includes penicillin and cephalosporin. Infection with MRSA can lead to a 
variety of sequelae, including ventilator-associated pneumonia, chronic wound infection, 
bloodstream infection (bacteraemia) and septic conditions, which in some circumstances can 
lead to death.  
 
The prevalence of MRSA varies across Europe, with a general trend of increasing prevalence 
from north to the south [2-4]. The reasons for these observed differences are not yet fully 
understood, although variation in prevention and control strategies [5], design of healthcare 
facilities [6], staff to patient ratios [7], patterns of antibiotic usage [8] and the implementation 
of antibiotic stewardship [9, 10] are thought to be contributing factors. As travel between 
European states becomes more common, with citizens free, within certain limits, to pursue 
elective treatment in a European country other than their own, the scope for transmission of 
infectious pathogens to areas where they are not endemic becomes ever greater [11, 12]. 
Therefore, cross border regions now face a particular challenge in coping with patients 
coming from neighbouring countries where different regulations and practices are in place to 
prevent, detect and respond to infectious agents [13]. This issue has led to the formation of a 
number of MRSA networks, founded on bilateral agreements between countries with shared 
borders about how best to manage the issues outlined above.  
 
Increases in the burden associated with HCAIs and the growth of antimicrobial resistance 
have led to heightened awareness both within the lay population and among politicians. The 
Chief Medical Officer in the UK has even gone so far as to place the threat posed by 
antimicrobial resistant on a par with that of terrorism [14]. The European Centre for Disease 
Prevention and Control (ECDC) has placed the “Antimicrobial Resistance and Healthcare-
associated Infections Programme” among its top priorities for the future [15]. The ECDC has 
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also stated that a major part of the problem stems from deficiencies in the way health related 
issues are communicated, and has encouraged EU member states to improve their risk 
communication strategies [16].  
 
Risk communication is a wide and multi-faceted field, and is considered an important 
approach in the fight against the spread of infectious diseases through the impact it can have 
on the adoption of appropriate behaviours e.g. frequent hand washing to limit carriage and 
infection [17]. Recent research has highlighted a number of areas which are key to 
understanding effective risk communication, such as the nature and quality of information 
provided to patients and health care workers [18], patients’ and the general public's perceived 
information needs [19, 20] and role of the media [21]. However, little research has been 
carried out into the impact of institutional arrangements on specific risk communication 
strategies.   
 
We conceptualise risk communication as not simply explicit communications, but also the 
implicit messages of institutional arrangements (differences in policies, inconsistencies of 
implementation, etc.). In order to test this assumption, we examined the implementation of 
various MRSA policies across five European countries for any evidence that environmental 
factors contribute as implicit and ‘autonomous’ risk communication next to traditional 
explicit and ‘voluntary’ forms.  
 
 The article begins by discussing the situation in each of the countries with regards to the 
following areas, while reflecting on the underlying epidemiological rationale for each:  
 Data and reporting mechanisms, 
 Regulations and guidelines, 
 Health policy approaches with a focus on risk communication, and 
 Implicit messages of current practices. 
 
In the second section, we move on to discuss how different national strategies to contain 
MRSA infection are implicit ‘messages’ and contribute to explicit also correspond to risk 
communication strategies.  
 
Methods 
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We collected information on the situation with regards to MRSA in five European countries: 
Austria, Germany, Netherlands, Spain and the UK. These countries were chosen as they 
represent varying prevalence, response strategies, overall health system organization and 
modes of communication.  
 
A template was designed to systematically collect information about five areas: 1) data 
collection and reporting mechanisms; 2) the regulatory framework; 3) clinical guideline 
design; 4) implementation of guidelines and 5) other relevant health policy measures. The 
intended and unintended effects of policies in each of these categories were then compared to 
explicit communication strategies first by country, and then across countries. Information was 
drawn from scientific and grey literature and complemented, where necessary, by stakeholder 
interviews.  
 
Results  
To help interpret the results, and how the various measures compare to one another, we 
developed a stepwise classification for different stages of MRSA (see Table 1).  
 
Table 1: Classification of MRSA from an infection control perspective 
 
Table 2: Overview: MRSA in five EU countries 
 
Data situation 
Comprehensive data on prevalence is difficult to obtain as most mandatory and voluntary 
surveillance systems were found to only cover MRSA bacteraemia. Point prevalence studies 
and surveys that have attempted to capture the situation have also been based on information 
provided by hospitals on a voluntary basis. This has contributed to the sporadic nature of 
evidence around MRSA and thus current data does not appropriately reflect the ubiquitous 
nature of the treat of infection [3]. The majority of countries (Austria, Germany, Spain, UK) 
only report bacteraemia (level III), which is the most serious consequence of infection and 
only present in a minority of cases. The UK, however, also screen for MRSA status prior to 
elective surgery, but this information is not officially reported. The Netherlands stands out 
with frequent reporting of colonisation and infection (level I and II).  
Moving the reporting downstream with the reporting of bacteraemia, level III, is posited to be 
one way to keep the absolute numbers down. In regards to communication, this could 
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contributes to keeping perception of infection rates artificially low. This is could be appealing 
to policy makers as the small reported cause less concern than if the true prevalence of 
infection were to be revealed [22-24]. It is, however, only an artefact of the reporting – and 
not reflective of the underlying epidemiology of the infectious disease. There is no consistent 
information about the “contagious burden”, meaning the provision of information about 
colonisation and infections, from level I on where MRSA is contagious and can be passed to 
others [25].  
 
Regulatory bodies 
Regulatory bodies are built based on the political structure of the country where they are 
based. In Austria, Germany and Spain health care provision and management is in the 
responsibility of federal states or autonomous communities. The Netherlands and the United 
Kingdom follow a national approach. Having different regulatory bodies could possibly lead 
to variability in terms of guidelines and recommendations and their implementation. The 
variability of recommendations within and across countries could contribute to the perception 
of inconsistency.  
 
Guidelines 
The Netherlands has opted to pursue an active screening policy (“search & destroy”). Risk-
based testing is in place in Austria, Germany, Spain and the UK, with the UK requiring 
screening of elective admissions to hospitals. Isolation practice for positive cases is basically 
the same in the five countries. However, the time lag between entering the hospital and being 
identified as MRSA carrier is critical as a variety of admission procedures, examinations and 
clinical investigations at the beginning of a hospital stay increase the likelihood to spread 
infectious diseases. The Netherlands, again, stand out by placing patients with an unknown 
MRSA status in isolation rooms; Spain places patients awaiting their results in isolation as 
well as, whenever possible (individual room availability), those who are previous carriers or 
high risk patients (in one autonomous community Catalonia). 
Healthcare workers in the four countries (Austria, Germany, Spain, UK) are not screened on a 
regular basis, meaning that those who are a high risk group in every countries’ guidelines and 
work where the contracting and spread of infectious disease occurs most readily are unaware 
of their own MRSA status [26]. The Netherlands screen staff regularly.  
The rigor of infection control is not appropriately reflected in the guidelines: MRSA patients 
are constantly contagious and not only after identification; healthcare worker fall under the 
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risk groups for screening in every country, but are, with the exception of the Netherlands, not 
screened.  
 
Implementation 
All countries investigated have put legal obligations in place to implement their guidelines. 
However, only sporadic, if any, verifications and checks are being carried out. Concerns 
about the implementation of the guidelines are frequently raised. SA recent surveys from 
Germany and the UK supports these findings. The authors showed that a minority of the 
hospitals have consistently implemented guidelines [27-28]. 
 
Health policy 
All the countries under investigation have increased their awareness for MRSA and have 
developed national action plans, regional and international networks of hospitals and 
laboratories, antibiotic stewardship, strengthened their legislation and created incentives to 
reduce the prevalence of MRSA [9]. The consistent adoption of this policy in the guidelines 
and the implementation into the daily practice is, however, subject to discussion. The gap 
between the policy and its implementation is not just a medical problem, but also influences 
the perception of health risks, and could affect compliance with the intended behaviour [29].  
 
Communication 
Information and knowledge play a crucial role in the management of MRSA, and European 
health policy also puts special attention on communication. All five countries thus prioritise 
the provision of information to various target groups (health professionals, patients and 
general public). The explicit information strategy, however, is only one aspect of this 
(“voluntary communication”); another aspect is how messages that are expressed in the 
official statements are ‘executed’ on the ground of the daily reality of health care 
(“autonomous communication”). Infection control measures, their implementation into the 
medical environment and their frictions are tacit acts of communication yet little attention has 
been spent on how to monitor and improve the way they contribute to the conveyance of key 
health messages.  
 
Discussion 
Epidemiological rationale  
Infection control approach 
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There are, generally speaking, two basic strategies for responding to infectious diseases that 
emerge from the analysis: a ‘specific’ and a ‘general’ approach. 
The specific approach relies on the identification of those patients already infected with 
MRSA. Once an MRSA patient is identified and known (‘red flagged’), appropriate measures 
can be taken. These measures range from sanitation of skin colonisation and/or treatment of 
the infection. The patient should also be isolated from the hospital environment in order to 
prevent the transmission of the pathogen. Once an MRSA patient has been identified, health 
care workers have to wear personal protection equipment and apply stringent hygiene 
measures. The MRSA patient’s room is often labelled with a sign signalling the contagious 
status. There is a general consensus regarding isolation and hygiene practices. However, the 
crucial choice of strategy for identification in the specific approach is controversial. Only the 
Netherlands has a pro-active screening policy; all of the other countries studied used a process 
of reactive screening based on risk assessment, with the UK also requiring pre-hospital 
screening for elective admissions. Hospitals across the four ‘reactive’ EU countries (Austria, 
Germany, Spain, UK) appear very reluctant to screen patients for a number of reasons. One is 
that the care for and treatment of MRSA patients places greater demands on the attending 
nurses and clinicians, meaning that there could be an incentive to avoid correct MRSA 
classification. Additional measures such as spatial requirements (single isolation rooms), 
differential treatment guidelines, and consequences for staff and ward routines aggravate the 
situation. Also at the hospital level it ostensibly requires more time and resources to care for 
MRSA patients and therefore those facing budgetary pressure may possibly be more inclined 
to avoid diagnosis, despite the fact that the costs of cases progressing to bacteraemia may 
outweigh the costs of an active screening policy [30-34]. 
If contagious patients are not identified, a ‘general’ approach with stringent measures to 
guarantee good hygiene has to be adhered to by all healthcare workers, patients and visitors. 
This system of infection control includes, among others, requirements such as strict hand 
hygiene, regular cleaning and disinfection of surfaces. To promote the general hygiene 
approach good communication is crucial to ensure that everyone is aware of what they need 
to do in order to avoid infection and stop further spread. Frictions between infection 
management and communication could affect the adoption of the recommended behaviour.  
 
Ethical Problems 
The handling for MRSA patients raises some ethical questions regarding whether there is 
equal treatment of isolated and contagious patients. The restriction of physical transport and 
Formatat: Interlineat:  1,5 línies
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transfer forms part of the infection control recommendations in the European countries 
investigated. However, it is an increasingly controversial and sensitive aspect of the 
prescribed treatment of MRSA patients as many feel it could compromise the quality of 
clinical care [35]. Most guidelines recommend that some invasive interventions be confined 
to the room used by MRSA patients [36]. In the case where interventions performed in the 
patient’s room would be better carried out elsewhere, the lack of an optimal environment can 
lead to reduced performance on the part of clinicians. Infectious patients are put at the end of 
the day’s surgery schedule and are more likely to be postponed due to emergencies in the 
surgical programme. The avoidance of invasive diagnostics alongside being the “last 
operation on the schedule” could comprise the medical treatment of an often critically ill 
patient.  
 
Organisational Aspects 
MRSA is also an occupational health problem. Healthcare workers are not routinely screened 
for MRSA colonisation or infection - apart from in the Netherlands. This reluctance to 
identify infectious staff could be seen in the context of healthcare organisation. If a staff 
member is colonised with MRSA they are not allowed to work in their usual locations. This 
poses a burden to the workplace organisation in terms of the potential for inconsistent labour 
supply, in particular in an already overstretched working environment. Hospitals and 
countries in which the intensive care unit (ICU) carer/nurse to patient ratio is 1:1 report 
basically no problems of nosocomial infections [37]. This adds weight to the hypothesis that a 
major contributor to increasing prevalence of MRSA is the high patient-healthcare worker-
ratio [38].  
 
Architecture 
The guidelines also point out the importance of spatial distancing and the role of architecture 
– a challenge which has not been met by modern hospitals and it remains unclear whether this 
concern regarding the spread of infectious disease will be met in the future [6]. 
 
Risk communication strategy 
The ‘general’ approach i.e. the basic tools for fighting an infectious disease epidemic, all 
feature prominently in all national guidelines: knowledge, training, information, networks and 
collaboration. But the question remains of how well are the recommendations implemented at 
the provider levels especially in terms of their risk communication practices.  
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Conflicting messages 
From a patient perspective, the discharge of MRSA patients is an ostensibly incongruent 
routine. After being treated in strict isolation and under a stringent hygiene regimen – patients 
are simply discharged and informed that MRSA is no risk for healthy people [39]. This 
dissonance could lead to confusion and distress for patients, relatives and visitors and adds 
further to potential misperceptions of their health risk to others.  
 
Knowledge  
Despite the laws and efforts surrounding improving information and communication, 
knowledge levels have been mixed. The lack of knowledge in healthcare professionals is seen 
as an influencing factor for increasing prevalence of nosocomial infections [40-43].  
 
Risk communication policy  
The risk communication policies of the five EU countries  were found to contain only 
information relating to risks faced by people directly involved in healthcare, such as hospital 
staff and patients. These policiesy is were based on the same risk assessment thatas is used to 
determine which patients should be screened for MRSA. It focuses on healthcare workers, 
long term care, chronically ill patients and patients facing surgery. There has only been little 
effort to address MRSA as problem in and for the general population [44]. This narrow view 
is congruent with the lack of concern for the role of other factors, The entire field of 
contributing risk communication factors such as behaviour, implementation of guidelines, 
etc.etc., is not reflectedseen in other areas.  
 
Media Coverage 
The consensus in the literature is that the UK media coverage, especially within the tabloid 
newspapers, has been at times sensationalist. However, the pressure placed on governments in 
response to the extensive media coverage has played a significant role in a number of policy 
changes which have contributed to the decline in incidence of deaths and bacteraemia 
associated with MRSA [45-46].  
 
Public Perception  
The infection threat posed by MRSA is difficult to communicate. Researchers have blamed 
contradicting risk communication about necessary hygienic measures as one problem [47]. 
They see that even necessary cleaning routines have not been implemented in hygiene plans 
[47]. More importantly, risk communication messages might have influenced the risk 
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perception of healthcare workers, patients and the public inappropriately. The message that 
MRSA is not an infectious diseases agent which can lead to outbreaks outside of healthcare 
facilities and also does not do harm to family members has direct consequences for the 
epidemiology of MRSA, and could in turn have led to the perception that MRSA is a 
harmless pathogen only affecting those who are already ill [39]. 
 
Conclusion 
The data situation in the countries is patchy at best, and thus it is difficult to offer up any firm 
conclusions regarding the overall burden of disease in the countries studied. What is clear, 
however, is that knowledge and information about the infectious disease burden is limited in 
the general population, and this lack of clarity has led to a growth in misconceptions 
surrounding the threat of MRSA. 
   
The variability of recommendations within, and across, countries could be contributing to the 
perception of inconsistency and therefore this should be looked, potentially as part of a wider 
strategy designed to improve risk communication Having inconsistent guidelines and 
practices in place may also be affecting the level at which recommended behaviours are 
adopted. 
 
The risk communication of MRSA has several weaknesses: there are misleading messages in 
the official statements and a gap between the official communications and guidelines, with 
inconsistent adoption of the latter at the provider level.  
This discrepancy between the official, explicit health messages around MRSA and the 
implicit messages stemming from the performance of infection control measures should 
therefore be a key target for those wishing to improve the accuracy of perceptions regarding 
the health risks of MRSA.  
 
Recommendation 
The increasing burden of antimicrobial resistance and health care associated infections has 
been reflected in growing public awareness, for example with major health policy 
organisations urging countries to improve their risk communication and MRSA prevention 
strategies. These ought to be revised to also address the general public. Thus far, most 
countries have adopted a universal risk-based approach addressing affected groups, without 
differentiating between groups, or addressing the wider public. Health policy and practice has 
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also focused on individual infection control measures and place the majority of responsibility 
on the individual. Organizational aspects (patient- healthcare worker ratios, architecture, etc.) 
have not been prominently discussed. The rational use of antibiotics and antibiotic 
stewardship is a significant move designed to place greater responsibility for the control if 
HCAIs on medical professionals. However, the key message, often included in national risk 
communication strategies, that MRSA is a problem only for those who are already ill, is 
misleading. In fact, MRSA is a problem affecting society as a whole. MRSA is a problem for 
healthy people as they can transmit the disease; MRSA is a problem for treating too many 
patients in too narrow spaces. MRSA is a problem because MRSA patients are only 
reluctantly identified. And finally, MRSA is a problem because the explicit and implicit 
messages of MRSA are often inconsistent if not contradictory.  
The problem of health care related infections and antimicrobial resistance can only be tackled 
in a more holistic approach regarding reconsideration of affected groups, healthcare 
organisation, architecture and a rational use of antibiotics – and by revising a risk 
communication strategy accordingly.  
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